Abstract：【Objective】To investigate the effects of labelore combined with enoxaparin on blood pressure level and its safety in patients with hypertensive diseases in pregnancy. 【Methods】 One hundred and two patients with gestational hypertension admitted to our hospital from June 2017 to June 2018 were randomly divided into two groups. The control group was treated with oral labetalol tablets, and the study group was treated with labetalol combined with enoxaparin. The clinical therapeutic effect, blood pressure level, 24 h urinary protein level, blood lipid level before and after treatment, and the incidence of adverse reactions and severe adverse pregnancy outcomes were compared between the two groups. 【Results】The total effective rate was 94.1% (48/51) in the observation group, which was significantly higher than 78.4% (40/51) in the control group. The difference was statistically significant (χ2=7.318,P<0.05). Before treatment, there was no significant difference in blood pressure and 24-hour urinary protein between the two groups (P>0.05); after treatment, the above indicators in both groups decreased significantly compared with before treatment (P<0.05), and the observation group decreased more significantly (P<0.05). Before treatment, there was no significant difference in blood lipid levels between the two groups (P>0.05); after treatment, the levels of LDL-C, TC and TG in the two groups were significantly lower than those before treatment, and the levels of HDL-C were significantly higher than those before treatment, and the observation group was significantly better than those before treatment. The control group (P<0.05). Compared with the control group, the incidence of adverse pregnancy outcomes such as premature delivery, postpartum hemorrhage, fetal distress and neonatal asphyxia in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). The total incidence of adverse reactions was 39.22% (20/51) in the observation group and 35.29% (18/51) in the control group. There was no significant difference between the two groups (P>0.05). The adverse reactions in the two groups were mild and improved by symptomatic treatment without affecting the follow-up treatment.【Conclusion】Labellol combined with enoxaparin in the treatment of pregnancy-induced hypertension can significantly reduce blood pressure and 24-hour urinary protein levels, reduce the incidence of adverse pregnancy outcomes, and has high safety, which is worthy of clinical application.
傅红. 拉贝洛尔联合依诺肝素治疗妊娠期高血压疾病疗效观察[J]. 医学临床研究, 2019, 36(9): 1677-1680.
FU Hong. Effect of Labellol Combined with Enoxaparin on Hypertensive Patients During Pregnancy. JOURNAL OF CLINICAL RESEARCH, 2019, 36(9): 1677-1680.
2019, Vol. 36 
